Investors Buy Shares of Humana (HUM) on Weakness

Investors purchased shares of Humana Inc (NYSE:HUM) on weakness during trading hours on Monday. $137.41 million flowed into the stock on the tick-up and $59.43 million flowed out of the stock on the tick-down, for a money net flow of $77.98 million into the stock. Of all companies tracked, Humana had the 14th highest net in-flow for the day. Humana traded down ($5.78) for the day and closed at $258.55

Several equities analysts recently weighed in on HUM shares. Credit Suisse Group cut their price objective on shares of Humana from $256.00 to $246.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. ValuEngine lowered shares of Humana from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. BMO Capital Markets lifted their price target on shares of Humana from $290.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 10th. Jefferies Group reissued a “hold” rating and issued a $257.00 price target on shares of Humana in a research report on Friday, October 13th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $242.00 price target (down previously from $245.00) on shares of Humana in a research report on Thursday, November 9th. Twelve research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $258.62.

The firm has a market cap of $36,960.00, a P/E ratio of 20.36, a PEG ratio of 1.74 and a beta of 0.88. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.61.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, November 8th. The insurance provider reported $3.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 3.49% and a return on equity of 15.99%. Humana’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the company posted $3.18 earnings per share. research analysts forecast that Humana Inc will post 11.63 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $1.60 annualized dividend and a dividend yield of 0.62%. Humana’s payout ratio is 12.60%.

Humana announced that its Board of Directors has initiated a stock repurchase program on Thursday, December 14th that authorizes the company to repurchase $3.00 billion in outstanding shares. This repurchase authorization authorizes the insurance provider to buy shares of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

In other news, SVP Brian P. Leclaire sold 1,679 shares of the firm’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $245.97, for a total value of $412,983.63. Following the sale, the senior vice president now owns 9,888 shares in the company, valued at $2,432,151.36. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Timothy S. Huval sold 1,382 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the sale, the vice president now owns 11,557 shares in the company, valued at approximately $2,843,484.28. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,115 shares of company stock worth $2,501,627. 0.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Humana by 1.6% during the second quarter. Vanguard Group Inc. now owns 9,892,635 shares of the insurance provider’s stock worth $2,380,366,000 after buying an additional 157,868 shares in the last quarter. FMR LLC boosted its stake in Humana by 29.3% during the second quarter. FMR LLC now owns 6,530,063 shares of the insurance provider’s stock worth $1,571,264,000 after buying an additional 1,479,210 shares in the last quarter. Capital Research Global Investors boosted its stake in Humana by 9.7% during the second quarter. Capital Research Global Investors now owns 3,907,333 shares of the insurance provider’s stock worth $940,182,000 after buying an additional 346,069 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Humana by 1.5% during the second quarter. Renaissance Technologies LLC now owns 2,731,100 shares of the insurance provider’s stock worth $657,157,000 after buying an additional 39,400 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in Humana by 74.1% during the third quarter. Janus Henderson Group PLC now owns 2,729,248 shares of the insurance provider’s stock worth $664,921,000 after buying an additional 1,161,661 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

WARNING: “Investors Buy Shares of Humana (HUM) on Weakness” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.com-unik.info/2018/01/08/investors-buy-shares-of-humana-hum-on-weakness.html.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

What are top analysts saying about Humana? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit